20 hours Ago
thomas-bethge/iStock via Getty Images Investment Overview Supernus ( NASDAQ: SUPN ), the Rockville, Maryland headquartered developer of drugs to treat central nervous system ("CNS") conditions, will announce its Q1 2025 earnings next Tuesday, 6th May. Supernus is a stock I hold, and I gave it a "Buy" rating If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research.
I hope to see you there. Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies.
He leads the investing group Haggerston BioHealth . Learn more Analyst’s Disclosure: I/we have a beneficial long position in the shares of SUPN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions.
I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.
No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body..
